Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Notes Payables: 2009-2012

Historic Notes Payables for Ani Pharmaceuticals (ANIP) over the last 1 years, with Dec 2012 value amounting to $4.1 million.

  • Ani Pharmaceuticals' Notes Payables was N/A to $4.1 million in Q4 2012 from the same period last year, while for Dec 2012 it was $4.1 million, marking a year-over-year change of. This contributed to the annual value of $4.1 million for FY2012, which is N/A change from last year.
  • Per Ani Pharmaceuticals' latest filing, its Notes Payables stood at $4.1 million for Q4 2012, which was up 229.42% from $1.2 million recorded in Q3 2011.
  • In the past 5 years, Ani Pharmaceuticals' Notes Payables ranged from a high of $16.7 million in Q4 2009 and a low of $1.1 million during Q4 2010.
  • Over the past 3 years, Ani Pharmaceuticals' median Notes Payables value was $1.2 million (recorded in 2011), while the average stood at $1.7 million.
  • Data for Ani Pharmaceuticals' Notes Payables shows a maximum YoY slumped of 93.34% (in 2010) over the last 5 years.
  • Quarterly analysis of 4 years shows Ani Pharmaceuticals' Notes Payables stood at $16.7 million in 2009, then crashed by 93.34% to $1.1 million in 2010, then reached $1.2 million in 2011, then reached $4.1 million in 2012.
  • Its Notes Payables was $4.1 million in Q4 2012, compared to $1.2 million in Q3 2011 and $1.2 million in Q2 2011.